FilingReader Intelligence

Tiantan Biological abandons Pailin Biotech acquisition citing integration risks

August 4, 2025 at 09:32 AM UTCBy FilingReader AI

Beijing Tiantan Biological Products Corp. will abandon its acquisition of 21.03% of Pailin Biotech, citing high transaction timelines and potential integration risks.

The decision defers the acquisition to its controlling shareholder, China National Biotec Group, which will address the resulting horizontal competition issues.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Beijing Tiantan Biological Products Corp publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →